These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 38341165)

  • 21. Denosumab-induced severe hypocalcaemia in a patient with vitamin D deficiency.
    Daga N; Joseph F
    BMJ Case Rep; 2020 Aug; 13(8):. PubMed ID: 32847872
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hypocalcaemia after denosumab in older people following fracture.
    Chen J; Smerdely P
    Osteoporos Int; 2017 Feb; 28(2):517-522. PubMed ID: 27682248
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Denosumab-Associated Severe Hypocalcemia in a Patient With Chronic Kidney Disease.
    Salim SA; Nair LR; Thomas L; Garla V; Palabindala V; Agarwal M; Fülöp T
    Am J Med Sci; 2018 May; 355(5):506-509. PubMed ID: 29753381
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Denosumab causing severe, refractory hypocalcaemia in a patient with chronic kidney disease.
    Saleem S; Patel S; Ahmed A; Saleem N
    BMJ Case Rep; 2018 May; 2018():. PubMed ID: 29848528
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Osteoporosis Drug Increases Hypocalcemia Risk in Dialysis Patients.
    Aschenbrenner DS
    Am J Nurs; 2023 Mar; 123(3):20. PubMed ID: 36815815
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mineral and bone disorders in conventional hemodialysis: Challenges and solutions.
    Hamano T
    Semin Dial; 2018 Nov; 31(6):592-598. PubMed ID: 29900589
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy of switching from teriparatide to zoledronic acid or denosumab on bone mineral density and biochemical markers of bone turnover in older patients with severe osteoporosis: a real-life study.
    Dito G; Lugaresi M; Degradi C; Guabello G; Longhi M; Corbetta S
    Endocrine; 2023 Oct; 82(1):181-189. PubMed ID: 37402061
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment of osteoporosis with denosumab in patients with decreased kidney function.
    Svendsen OL
    Arch Osteoporos; 2023 Jul; 18(1):104. PubMed ID: 37495795
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Denosumab-associated hypocalcaemia: incidence, severity and patient characteristics in a tertiary hospital setting.
    Huynh AL; Baker ST; Stewardson AJ; Johnson DF
    Pharmacoepidemiol Drug Saf; 2016 Nov; 25(11):1274-1278. PubMed ID: 27255807
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Vertebral Fractures Following Denosumab Discontinuation in Patients with Prolonged Exposure to Bisphosphonates.
    Tripto-Shkolnik L; Rouach V; Marcus Y; Rotman-Pikielny P; Benbassat C; Vered I
    Calcif Tissue Int; 2018 Jul; 103(1):44-49. PubMed ID: 29396698
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Denosumab-induced severe hypocalcemia in a patient with Paget's disease of bone and impaired renal function.
    Kostine M; Mehsen-Cetre N; Bannwarth B
    Therapie; 2017 Jun; 72(3):383-385. PubMed ID: 27745697
    [No Abstract]   [Full Text] [Related]  

  • 32. Denosumab for dialysis patients with osteoporosis: A cohort study.
    Kunizawa K; Hiramatsu R; Hoshino J; Mizuno H; Ozawa Y; Sekine A; Kawada M; Sumida K; Hasegawa E; Yamanouchi M; Hayami N; Suwabe T; Sawa N; Ubara Y; Takaichi K
    Sci Rep; 2020 Feb; 10(1):2496. PubMed ID: 32051451
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Acute hypocalcaemia following denosumab in heart and lung transplant patients with osteoporosis.
    Shrosbree JE; Elder GJ; Eisman JA; Center JR
    Intern Med J; 2018 Jun; 48(6):681-687. PubMed ID: 29363863
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Severe hypocalcemia after denosumab administration in a patient with chronic kidney disease: a case report.
    Kouroglou E; Tsiama V; Dionysopoulou S; Gavriiloglou G; Bora M; Belis K; Proikaki S; Savvidis C; Giannou P; Petras D
    J Musculoskelet Neuronal Interact; 2023 Jun; 23(2):285-289. PubMed ID: 37259667
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Significant bone loss after stopping long-term denosumab treatment: a post FREEDOM study.
    Zanchetta MB; Boailchuk J; Massari F; Silveira F; Bogado C; Zanchetta JR
    Osteoporos Int; 2018 Jan; 29(1):41-47. PubMed ID: 28975362
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Denosumab in chronic kidney disease: a narrative review of treatment efficacy and safety.
    Gopaul A; Kanagalingam T; Thain J; Khan T; Cowan A; Sultan N; Clemens KK
    Arch Osteoporos; 2021 Jul; 16(1):116. PubMed ID: 34319515
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Denosumab Toxicity When Combined With Anti-angiogenic Therapies on Patients With Metastatic Renal Cell Carcinoma: A GETUG Study.
    Guillot A; Joly C; Barthélémy P; Meriaux E; Negrier S; Pouessel D; Chevreau C; Mahammedi H; Houede N; Roubaud G; Gravis G; Tartas S; Albiges L; Vassal C; Oriol M; Tinquaut F; Espenel S; Bouleftour W; Culine S; Fizazi K
    Clin Genitourin Cancer; 2019 Feb; 17(1):e38-e43. PubMed ID: 30279115
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hypophosphatemia and hungry bone syndrome in a dialysis patient with secondary hyperparathyroidism treated with cinacalcet--proposal for an improved monitoring.
    Nowack R; Wachtler P
    Clin Lab; 2006; 52(11-12):583-7. PubMed ID: 17175888
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety of denosumab in dialysis patients on calcium and vitamin D supplements.
    Ullah A; Abdulnabi K; Khalil A; Alexander J; Pai P; Mishra V
    Saudi J Kidney Dis Transpl; 2017; 28(1):158-161. PubMed ID: 28098118
    [No Abstract]   [Full Text] [Related]  

  • 40. Denosumab anf cronic kidney disease: Severe life-threatening hypocalcemia.
    Monge Rafael P; Martin de Francisco ÁL; Fernández-Fresnedo G
    Nefrologia (Engl Ed); 2018; 38(1):97-98. PubMed ID: 29325673
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.